YTTERBIUM YB 169 DTPA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for YTTERBIUM YB 169 DTPA (YTTERBIUM YB 169 DTPA).
Ytterbium Yb 169 DTPA is a radiopharmaceutical that emits gamma radiation. After administration, it distributes in the extracellular fluid and is cleared by glomerular filtration. Its mechanism of action is based on physical decay emission of photons for imaging, with no pharmacological effect.
| Metabolism | Not metabolized; cleared by glomerular filtration without biotransformation. |
| Excretion | Renal: >90% unchanged; biliary/fecal: <10% |
| Half-life | Terminal: 25-50 days (effective half-life due to physical decay of Yb-169); clinical context: imaging agent for cisternography, half-life reflects biological clearance with physical decay (T1/2 physical: 32 days) |
| Protein binding | Negligible (<5%) |
| Volume of Distribution | Vd: 0.15-0.25 L/kg (confined to extracellular space and CSF) |
| Bioavailability | Intrathecal: 100% (as administered); IV: 100% |
| Onset of Action | Intrathecal: immediate (distribution within CSF) within minutes; IV: rapid distribution within 1-2 hours |
| Duration of Action | Intrathecal: imaging adequate for 24-48 hours; IV: imaging window 1-4 hours post-injection |
No standard therapeutic dosing; used as a diagnostic radiopharmaceutical. Typical adult activity: 37-111 MBq (1-3 mCi) intravenous injection for cisternography or CSF shunt evaluation.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications established. Use with caution in severe renal impairment due to potential altered clearance; consider minimizing radiation exposure. |
| Liver impairment | No specific Child-Pugh based modifications. Primarily renally cleared; hepatic dysfunction unlikely to require dose adjustment. |
| Pediatric use | Weight-based: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg) intravenously, minimum dose to achieve adequate imaging; follow institutional pediatric radiopharmaceutical dosing guidelines. |
| Geriatric use | No specific elderly dose adjustments; consider age-related decline in renal function and use minimal effective activity to reduce radiation exposure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for YTTERBIUM YB 169 DTPA (YTTERBIUM YB 169 DTPA).
| Breastfeeding | Ytterbium Yb 169 DTPA is excreted in human breast milk. The milk-to-plasma ratio (M/P) is not specifically documented; however, radiopharmaceuticals may accumulate in milk. Breastfeeding should be interrupted for a period sufficient to allow radioactivity to decline (typically >1 half-life of 32 days for Yb-169), with consultation of institutional guidelines. Ensure expressed milk is discarded until advised otherwise. |
| Teratogenic Risk | Ytterbium Yb 169 DTPA is a radiopharmaceutical. Ionizing radiation exposure during pregnancy is associated with increased risks of fetal malformations, growth restriction, and carcinogenesis. The first trimester (organogenesis) poses the highest risk for teratogenesis; second and third trimester risks include growth impairment and neurodevelopmental effects. The absorbed dose to the fetus depends on maternal dose and radiopharmaceutical kinetics. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to ytterbium Yb 169 DTPA or any component","Pregnancy unless clearly needed"]
| Precautions | ["Radiation exposure risk; use only when necessary","Consider cumulative radiation dose in repeated studies","Allergic reactions possible but rare","Pregnancy and lactation: use only if benefit outweighs risk"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal thyroid function (due to potential radioiodine uptake in thyroid) and radiation exposure via dosimetry. Assess fetal dose using standard MIRD methods; consider alternative imaging modalities if possible. Monitor for signs of maternal hypersensitivity reactions. Follow institutional radiation safety protocols. |
| Fertility Effects | No specific data on Yb-169 DTPA and fertility. Ionizing radiation at diagnostic doses (typically <50 mSv) is unlikely to cause permanent fertility impairment. However, animal studies suggest potential for ovarian damage and impaired spermatogenesis at high doses; clinical relevance at diagnostic levels is minimal. |